Inhibrx Reports Strong Phase 2 Data for INBRX-106 in HNSCC, Plans Phase 3 & NSCLC Expansion

summarizeSummary

Inhibrx Biosciences announced highly positive interim Phase 2 results for INBRX-106 in Head and Neck Squamous Cell Carcinoma, showing a significant increase in objective response rate and complete responses, with plans to advance to Phase 3 and expand into other indications.

check_boxKey Events

• Positive Phase 2 HNSCC Data

  INBRX-106 in combination with pembrolizumab achieved a 44.0% confirmed objective response rate (cORR) in first-line Head and Neck Squamous Cell Carcinoma (HNSCC), compared to 21.4% for pembrolizumab alone, representing a 22.6% absolute increase.

• Complete Responses Observed

  Three complete radiographic responses were observed in the INBRX-106 combination arm, while no complete responses were seen with pembrolizumab monotherapy.

• Mechanistic Validation

  Pharmacodynamic data supported the clinical findings, showing up to a 15-fold increase in T-cell proliferation and up to a four-fold increase in activation in combination-treated patients, consistent with INBRX-106's mechanism of action as a potent T-cell costimulator.

• Advancing to Phase 3

  The company plans to initiate the Phase 3 portion of the HexAgon study in Q3 2026, with progression-free survival data from Phase 2 expected in Q4 2026.

auto_awesomeAnalysis

This filing details compelling interim Phase 2 data for INBRX-106, demonstrating a substantial improvement in confirmed objective response rates and complete responses in first-line HNSCC when combined with pembrolizumab. These results validate the drug's mechanism of action and support its potential to enhance checkpoint inhibitor efficacy across multiple large indications, including non-small cell lung cancer, representing a significant expansion of the company's pipeline opportunity. The planned initiation of a Phase 3 study and further clinical development in other settings will be key milestones to watch.